Advances in Chronic Lymphocytic Leukemia Microenvironment: The Disruption of the Supportive Leukemic/Accessory Cells Interactions to Improve Therapy Response, 2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 98
Special Issue Editors
Interests: lymphoproliferative disorders; tumor microenvironment; cytokines; myeloid suppressor cells
Special Issues, Collections and Topics in MDPI journals
Interests: tumor microenvironment; mesenchymal stem cells; growth factors; microenvironment in vitro models
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This collection is the second edition of the previous one, entitled "Advances in Chronic Lymphocytic Leukemia Microenvironment: The Disruption of the Supportive Leukemic/Accessory Cells Interactions to Improve Therapy Response" (https://www.mdpi.com/journal/cancers/special_issues/163TN7M343).
Chronic Lymphocytic leukemia (CLL) is a lymphoproliferative disorder characterized by the relentless accumulation of leukemic B cells in the blood, secondary lymphoid tissue, and bone marrow. It has become increasingly clear that the stimuli derived from the cross-talk between the neoplastic cells and the microenvironment have a critical role in CLL-pathogenesis; this finding suggests the importance of disrupting survival advantages conferred by growth-favorable niches to improve the response to therapy. Indeed, several cytokines released within the microenvironment and specific cell–cell contacts favor clonal B cell expansion and resistance to drug treatments. It is further worth noting that leukemic B cells shape their microenvironment and polarize M1 vs. M2 or Th1 vs. Th2 cells, causing, therefore, the suppression of the immune response.
Novel therapeutic agents targeting the BCR signaling pathways can also be effective in modulating these interactions, but we still need to better understand cell-intrinsic and -extrinsic causes of therapy failure, further taking into account the opportunities for using combined therapies.
Today, the exploration of CLL–tumor–microenvironment (TME) interactions using innovative 3D models, mimicking more reliable and physiological neoplastic/accessory cells in in vivo settings, will further shed new light and be of interest to both research and clinical purposes.
This Special Issue encompasses new research articles and reviews that advance our knowledge of CLL–TME cross-talk and that highlight novel treatments optimized to reshape the protumor microenvironment and potentiate current therapies.
Dr. Daniela De Totero
Dr. Paolo Giannoni
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic lymphocytic leukemia
- tumor microenvironment
- cytokines targeted therapy
- combination therapy
- 2D/3D models of CLL–tumor microenviroment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
